Phase I Study of “Off-The-Shelf” Virus-Specific T Cells Published in BLOOD ADVANCES

Research published in the journal BLOOD ADVANCES established the feasibility of using a small bank of third-party cell lines generated from carefully chosen donors to provide virus-specific T-cell therapy to a large number of patients. The data show coverage of more than 95 percent of patients with cytomegalovirus (CMV) reactivation and associated diseases following allogeneic hematopoietic stem cell transplantation (HSCT). The Phase 1 study was conducted by researchers at Baylor College of Medicine’s Center for Cell and Gene Therapy, whose innovative technology platform formed the basis for AlloVir, a late-clinical stage allogeneic cell therapy company.

Read More
Andrews Technology Group
AlloVir Announces Viralym-M Granted Regenerative Medicine Advanced Therapy (RMAT) Designation

AlloVir, a late-clinical stage allogeneic T-cell therapy company, today announced that it has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for Viralym-M (ALVR105), its lead allogeneic, off-the-shelf, multi-virus specific T-cell therapy, for the treatment of hemorrhagic cystitis (HC) caused by BK virus in adults and children following allogeneic hematopoietic stem cell transplantation (HSCT)

Read More
ElevateBio Announces that AlloVir Joins its Portfolio of Highly Innovative Cell and Gene Therapy Companies

ElevateBio, a cell and gene therapy holding company, announced today that AlloVir, formerly known as ViraCyte, has joined its growing portfolio of highly innovative companies. AlloVir, a late-clinical stage allogeneic cell therapy company, is built on an innovative technology platform developed by researchers at Baylor College of Medicine’s Center for Cell and Gene Therapy.

Read More